ArticleBMC cancer2026
A population-based study on the impact of social determinants of health on time to treatment of stage I lung cancer in Ontario, Canada.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTimely treatment of Stage I non-small cell lung cancer (NSCLC) is essential to improving outcomes, yet disparities persist in access to treatment across patient populations. This study aimed to assess the association between social determinants of health (SDOH) and time to treatment for patients with Stage I NSCLC in Ontario, Canada.
methodsWe conducted a population-based retrospective cohort study using linked administrative databases. Adults diagnosed with Stage I lung cancer between 2007 and 2023 were included if they underwent either surgery or radiotherapy. Patients receiving chemotherapy, or surgery and radiotherapy were excluded. Flexible parametric models were used to evaluate associations between SDOH and time to treatment, stratified by treatment modality.
resultsAmong 10,734 patients with Stage I NSCLC, 7,366 (68.6%) received surgery only and 3,022 (28.2%) received radiotherapy only. Only 346 (3.2%) received both surgery and radiation. Increased time to treatment was significantly associated with advanced age (> 80 years: HR = 0.61, p < 0.001), higher comorbidity burden (> 5 comorbidities: HR = 0.80, p = 0.004), and being virtually rostered with a family physician (HR = 0.91, p = 0.001). Patients in the lowest neighbourhood income quintile had significantly longer time to treatment compared to higher quintiles (Q5: HR = 1.13, p < 0.001). Those living 50-100 km from a cancer centre experienced longer time to treatment (HR = 0.93, p = 0.011), as did patients treated in the Eastern region (HR = 0.79, p < 0.001) compared to those in the Central region. Time to treatment shortened over time, with improvements seen in 2015-2023 compared to 2007-2009.
conclusionsThis study identifies age, comorbidity, socioeconomic status, geographic distance, and regional location as key SDOH associated with prolonged time to treatment for Stage I NSCLC in Ontario. These findings highlight ongoing inequities in cancer care and underscore the need for targeted policy and system-level interventions to improve timely treatment for vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.